Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.41 |
| ▸ | BCL2 | P10415 | 7/20 | 0.37 |
| ▸ | BECN1 | Q14457 | 3/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.36 |
| ▸ | RORC | P51449 | 3/20 | 0.34 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1821764 | 0.88 | AKR1B1 (0.38) | BACE1AKR1B1NPSR1 | |
| SCHEMBL2376786 | 0.80 | BACE1 (0.42) | BACE1BCL2BECN1AKR1B1RORC | |
| SCHEMBL1824188 | 0.78 | ALDH1A1 (0.38) | BACE1AKR1B1 | |
| SCHEMBL7958777 | 0.76 | BACE1 (0.45) | BACE1BCL2BECN1AKR1B1RORC | |
| SCHEMBL1420964 | 0.72 | BACE1 (0.39) | BACE1 | |
| SCHEMBL12246352 | 0.66 | BACE1 (0.39) | BACE1BCL2BECN1AKR1B1 | |
| SCHEMBL14980625 | 0.66 | BACE1 (0.39) | BACE1RORC | |
| SCHEMBL12246365 | 0.65 | AKR1B1 (0.46) | AKR1B1SLC8A1NPSR1 | |
| SCHEMBL9932816 | 0.65 | BACE1 (0.40) | BACE1AKR1B1 | |
| Hydrochloric Acid SCHEMBL1822716 | 0.64 | AKR1B1 (0.45) | AKR1B1SLC8A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2324032-A2 | INHIBITORS OF BETA-SECRETASE | Vitae Pharmaceuticals, Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010021680-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-02-25 | — | — | WO | disclosed |